Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ALXO Alx Oncology Holdings Inc
- Stocks
- Healthcare
- NASDAQ: ALXO
Price (delayed)
$0.4594
Market cap
$24.55M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.45
Enterprise value
$13.91M
ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system.
Highlights
The EPS is up by 34% year-on-year and by 5% since the previous quarter
ALXO's net income is up by 22% year-on-year and by 3.6% since the previous quarter
The quick ratio has declined by 24% since the previous quarter but it has increased by 7% year-on-year
Alx Oncology Holdings's equity has decreased by 46% YoY and by 22% QoQ
The debt has grown by 2.8% year-on-year
Key stats
What are the main financial stats of ALXO
Market
Valuations
Earnings
Shares outstanding
53.44M
Market cap
$24.55M
Enterprise value
$13.91M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$136.53M
Net income
-$130.02M
EBIT
-$128.32M
EBITDA
-$127.45M
Free cash flow
-$109.01M
Per share
Balance sheet
Liquidity
EPS
-$2.45
EPS diluted
-$2.45
Free cash flow per share
-$2.04
Book value per share
$1.65
Revenue per share
$0
TBVPS
$2.27
Total assets
$120.9M
Total liabilities
$32.61M
Debt
$9.97M
Equity
$88.3M
Working capital
$83.79M
Debt to equity
0.11
Current ratio
5.47
Quick ratio
5.22
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-77.7%
Return on equity
-104.4%
Return on invested capital
-96.7%
Return on capital employed
-125.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALXO stock price
How has the Alx Oncology Holdings stock price performed over time
Intraday
-4.49%
1 week
-5.1%
1 month
-8.36%
1 year
-96.97%
YTD
-72.49%
QTD
-26.26%
Financial performance
How have Alx Oncology Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$136.53M
Net income
-$130.02M
Gross margin
N/A
Net margin
N/A
ALXO's operating income is up by 22% YoY and by 4.2% QoQ
ALXO's net income is up by 22% year-on-year and by 3.6% since the previous quarter
Price vs fundamentals
How does ALXO's price correlate with its fundamentals
Growth
What is Alx Oncology Holdings's growth rate over time
Valuation
What is Alx Oncology Holdings stock price valuation
P/E
N/A
P/B
0.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 34% year-on-year and by 5% since the previous quarter
The price to book (P/B) is 91% less than the 5-year quarterly average of 3.0 and 72% less than the last 4 quarters average of 1.0
Alx Oncology Holdings's equity has decreased by 46% YoY and by 22% QoQ
Efficiency
How efficient is Alx Oncology Holdings business performance
ALXO's return on equity is down by 15% year-on-year and by 11% since the previous quarter
ALXO's return on invested capital is down by 12% since the previous quarter and by 9% year-on-year
The return on assets has declined by 10% since the previous quarter and by 8% year-on-year
Dividends
What is ALXO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALXO.
Financial health
How did Alx Oncology Holdings financials performed over time
The total assets has declined by 43% year-on-year and by 18% since the previous quarter
The total liabilities has declined by 33% year-on-year and by 4.5% since the previous quarter
The debt is 89% smaller than the equity
Alx Oncology Holdings's debt to equity has soared by 83% YoY and by 22% from the previous quarter
Alx Oncology Holdings's equity has decreased by 46% YoY and by 22% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.